MCID: SYS046
MIFTS: 24

Systemic Lupus Erythematosus 3

Categories: Genetic diseases, Rare diseases, Nephrological diseases, Immune diseases, Bone diseases, Skin diseases

Aliases & Classifications for Systemic Lupus Erythematosus 3

MalaCards integrated aliases for Systemic Lupus Erythematosus 3:

Name: Systemic Lupus Erythematosus 3 54
Systemic Lupus Erythematosus, Susceptibility to, 3 13

Classifications:



External Ids:

OMIM 54 605480

Summaries for Systemic Lupus Erythematosus 3

MalaCards based summary : Systemic Lupus Erythematosus 3, also known as systemic lupus erythematosus, susceptibility to, 3, is related to systemic lupus erythematosus and lupus erythematosus. An important gene associated with Systemic Lupus Erythematosus 3 is SLEB3 (Systemic Lupus Erythematosus Susceptibility 3). The drugs Cyclophosphamide and Aspirin have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and t cells.

Description from OMIM: 605480

Related Diseases for Systemic Lupus Erythematosus 3

Symptoms & Phenotypes for Systemic Lupus Erythematosus 3

Clinical features from OMIM:

605480

Drugs & Therapeutics for Systemic Lupus Erythematosus 3

Drugs for Systemic Lupus Erythematosus 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 238)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 50-18-0, 6055-19-2 2907
2
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
3
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2 128794-94-5 5281078
4
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2 24280-93-1 446541
5
belimumab Approved Phase 4,Phase 3,Phase 2,Phase 1 356547-88-1 5957 10451420
6
Metformin Approved Phase 4 657-24-9 14219 4091
7
Sulfamethoxazole Approved Phase 4 723-46-6 5329
8
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
9
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-30-3 6037
10
leucovorin Approved, Nutraceutical Phase 4,Phase 3 58-05-9 143 6006
11 Vaccines Phase 4,Phase 2,Phase 3
12 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
13 Hormones Phase 4,Phase 3,Phase 2,Phase 1
14 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
15 Anticholesteremic Agents Phase 4,Phase 2,Phase 3,Phase 1
16 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1
17 Calcium, Dietary Phase 4,Phase 2,Phase 3,Phase 1
18 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
19 Hypolipidemic Agents Phase 4,Phase 2,Phase 3,Phase 1
20 Lipid Regulating Agents Phase 4,Phase 2,Phase 3,Phase 1
21 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Estrogens Phase 4,Phase 3,Phase 2
25 Estrogens, Conjugated (USP) Phase 4,Phase 3
26 Analgesics Phase 4,Phase 2,Phase 3
27 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3
28 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
29 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2
30 Antipyretics Phase 4,Phase 2,Phase 3
31 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Cyclooxygenase Inhibitors Phase 4
33 Fibrinolytic Agents Phase 4
34 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
35 Platelet Aggregation Inhibitors Phase 4
36 Rosuvastatin Calcium Phase 4,Phase 1 147098-20-2
37 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
38 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
39 Antimalarials Phase 4,Phase 3,Phase 2
40 Antiparasitic Agents Phase 4,Phase 3,Phase 2
41 Antiprotozoal Agents Phase 4,Phase 3,Phase 2
42 Folic Acid Antagonists Phase 4,Phase 3
43 Vitamin B Complex Phase 4,Phase 3,Phase 2
44 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
45 Hypoglycemic Agents Phase 4,Phase 1,Phase 2
46 Cytochrome P-450 Enzyme Inhibitors Phase 4
47 Renal Agents Phase 4
48 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
49 Adrenocorticotropic Hormone Phase 4
50 beta-endorphin Phase 4

Interventional clinical trials:

(show top 50) (show all 218)

id Name Status NCT ID Phase Drugs
1 Efficacy of Fish Oil in Lupus Patients Completed NCT00828178 Phase 4 Omega-3
2 Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With SLE: a Controlled Study Completed NCT00911521 Phase 4 human papillomavirus vaccination (Gardasil)
3 Effect of Hormone Replacement Therapy on Lupus Activity Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
4 Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus Completed NCT00371501 Phase 4 Rosuvastatin;placebo;aspirin;placebo
5 The Effect of Metformin on Reducing Lupus Flares Recruiting NCT02741960 Phase 4 metformin;placebo
6 Prophylactic Trimethoprim/Sulfamethoxazole to Prevent Severe Infections in Patients With Lupus Erythematous Recruiting NCT03042260 Phase 4 Trimethoprim-Sulfamethoxazole;Placebo Oral Tablet
7 ACTHar in the Treatment of Lupus Nephritis Recruiting NCT02226341 Phase 4 CellCept;ACTHar gel;ACTHar gel
8 Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE) Active, not recruiting NCT01632241 Phase 4 Standard therapy
9 Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
10 Study of GL701 in Men With Systemic Lupus Erythematosus Unknown status NCT00037128 Phase 3 GL701
11 An Open Labeled Pilot Study of Atorvastatin in Systemic Lupus Erythematosus Unknown status NCT00432354 Phase 2, Phase 3 atorvastatin
12 To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With Glucocorticoids Unknown status NCT00053560 Phase 3 Prasterone (GL701)
13 A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT00424476 Phase 3 Placebo;Belimumab 1 mg/kg;Belimumab 10 mg/kg
14 CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus Completed NCT01395745 Phase 3 blisibimod;Placebo
15 Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus Completed NCT01408576 Phase 3 Epratuzumab;Epratuzumab
16 A Study of Belimumab in Subjects With Systemic Lupus Erythematosus Completed NCT00410384 Phase 3 Placebo;Belimumab 1 mg/kg;Belimumab 10 mg/kg
17 A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT01484496 Phase 3 Standard therapy
18 Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus Completed NCT01262365 Phase 3 Epratuzumab;Epratuzumab;Placebo
19 Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE) Completed NCT01261793 Phase 3 Placebo;Epratuzumab;Epratuzumab
20 Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE) Completed NCT00624338 Phase 2, Phase 3 Atacicept 75 mg;Atacicept 150 mg
21 On Open-Label Study in Participants With Systemic Lupus Erythematosus Completed NCT01488708 Phase 3 LY2127399;Placebo
22 A Study of LY2127399 in Patients With Systemic Lupus Erythematosus Completed NCT01205438 Phase 3 LY2127399;Placebo every 2 weeks;Placebo every 4 weeks
23 A Study of LY2127399 in Patients With Systemic Lupus Erythematosus Completed NCT01196091 Phase 3 LY2127399;Placebo every 2 weeks;Placebo every 4 weeks
24 A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States Completed NCT00724867 Phase 3
25 A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057 Completed NCT00712933 Phase 3 belimumab
26 Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion Completed NCT01551069 Phase 3 hydroxychloroquine (Z0188);Placebo
27 GL701 (Prestaraâ„¢) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids Completed NCT00082511 Phase 3 Prasterone (GL701)
28 Study of Methotrexate in Lupus Erythematosus Completed NCT00470522 Phase 3 Methotrexate and folic acid
29 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Active Systemic Lupus Erythematosus Completed NCT00004662 Phase 3 dehydroepiandrosterone
30 A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG) Completed NCT00626197 Phase 3 corticosteroids;cyclophosphamide;mycophenolate mofetil;ocrelizumab;placebo
31 Dehydroepiandrosterone (DHEA) in Systemic Lupus Erythematosus (SLE) for Coronary Artery Disease (CAD) Prevention Completed NCT00189124 Phase 2, Phase 3 Dehydroepiandrosterone (DHEA)
32 Phase II/III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Mild to Moderate Systemic Lupus Erythematosus Completed NCT00004795 Phase 2, Phase 3 dehydroepiandrosterone
33 Safety Study of Two Vaccine Strategies in Patients With Systemic Lupus Erythematosus Completed NCT00611663 Phase 2, Phase 3
34 A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus Completed NCT00137969 Phase 2, Phase 3 Rituximab;Placebo;Prednisone;Acetaminophen;Diphenhydramine
35 Safety of Estrogens in Lupus: Birth Control Pills Completed NCT00000420 Phase 3 Ortho-Novum 777
36 Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease Completed NCT00035308 Phase 3 Abetimus sodium (LJP 394)
37 Alendronate Osteoporosis Study Completed NCT00277251 Phase 2, Phase 3 Alendronate
38 High-Dose Intravenous (IV) Cyclophosphamide Versus Monthly IV Cyclophosphamide Completed NCT00005778 Phase 3 High-dose immunoablative therapy
39 Efficacy and Safety of Influenza Vaccine During Sarcoidosis Completed NCT01687517 Phase 3 Seasonal influenza vaccine available for the 2012-2013 vaccine campaign
40 Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus Recruiting NCT02794285 Phase 3 Placebo
41 Evaluation of the Discontinuation of Maintenance Corticosteroid Treatment in Quiescent Systemic Lupus Recruiting NCT02558517 Phase 3 prednisone discontinuation
42 Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE Recruiting NCT02444728 Phase 3 Hydroxychloroquine;Cyclophosphamide;Azathioprine;Methylprednisolone
43 Efficacy and Safety of Abatacept in Patients With Primary Sjögren's Syndrome Recruiting NCT02067910 Phase 3 Abatacept SC
44 Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis Recruiting NCT01639339 Phase 3 Standard therapy
45 Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus Active, not recruiting NCT02446899 Phase 3 Placebo
46 Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus Active, not recruiting NCT02446912 Phase 3 Placebo
47 A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus Active, not recruiting NCT02504645 Phase 3 IPP-201101;Placebo
48 GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia Active, not recruiting NCT01345253 Phase 3 Belimumab;Placebo
49 BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115 Active, not recruiting NCT01597622 Phase 3 Belimumab
50 Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients Active, not recruiting NCT02119156 Phase 3 Belimumab

Search NIH Clinical Center for Systemic Lupus Erythematosus 3

Genetic Tests for Systemic Lupus Erythematosus 3

Anatomical Context for Systemic Lupus Erythematosus 3

MalaCards organs/tissues related to Systemic Lupus Erythematosus 3:

39
Skin, Bone, T Cells, Lung, Endothelial, B Cells, Ovary

Publications for Systemic Lupus Erythematosus 3

Articles related to Systemic Lupus Erythematosus 3:

id Title Authors Year
1
Studies of macrophage function in murine systemic lupus erythematosus. 3. The nature, anatomical location, and reversibility of the phagocytic defect. ( 3455711 )
1986
2
Family studies in systemic lupus erythematosus. 3. Presence of LE factor in relatives and spouses. ( 4124130 )
1972

Variations for Systemic Lupus Erythematosus 3

Expression for Systemic Lupus Erythematosus 3

Search GEO for disease gene expression data for Systemic Lupus Erythematosus 3.

Pathways for Systemic Lupus Erythematosus 3

GO Terms for Systemic Lupus Erythematosus 3

Sources for Systemic Lupus Erythematosus 3

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....